These combined effects not only improve the patient’s metabolic state but may also slow the progression of CKD and reduce the risk of cardiovascular complications, demonstrating the vast potential of SGLT-2 inhibitors in managing metabolic diseases. This evidence concerns the gene SLC5A2 and chronic kidney disease.